Please login to the form below

Yescarta

This page shows the latest Yescarta news and features for those working in and with pharma, biotech and healthcare.

Kite and Oxford BioTherapeutics sign oncology research pact

The main focus of that deal was Kite’s Yescarta (axicabtagene ciloleucel), the company’s first CAR-T therapy, which was approved in October 2017 for the treatment of adults with ... Yescarta was joined by Kite’s second CAR-T therapy Tecartus

Latest news

ASH 2020: Gilead eyes new Yescarta indication, Vertex/CRISPR make headway in sickle cell and more

Gilead’s Kite division presented new phase 2 data for its CAR T therapy Yescarta at ASH 2020 in relapsed or refractory high-risk large B-cell lymphoma (LBCL), a potential ... In the phase 2 ZUMA-12 study, after a single infusion of Yescarta
Gilead’s top-line slips 10% as demand for HIV/hepatitis C drugs drops

Sales of its Kite-partnered CAR-T cell therapy Yescarta (axicabtagene ciloleucel) climbed to $156m in the quarter, an increase on the $120m it generated for the same period in 2019.
GSK pays $50m upfront to tap Immatics’ cell therapy platform

Moreover, unlike currently-approved CAR-T therapies for cancer like Novartis’ Kymriah (tisagenlecleucel) and Gilead/Kite’s Yescarta (axicabtagene ciloleucel) which are approved for haematologic cancers, TCRs has the potential to
FDA begins speedy review of BMS’ CAR-T liso-cel

If it does receive approval, liso-cel will come onto the market after rival Novartis’ Kymriah (tisangenlecleucel) and Gilead Sciences’ Yescarta (axicabtagene ciloleucel). ... BMS alleged that Kite scientists copied research from the scientists at
FDA starts priority review of Kite’s CAR-T for mantle cell lymphoma

Gilead/Kite’s approved CAR-T therapy Yescarta (axicabtagene ciloleucel) is available for the treatment of diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma.

More from news
Approximately 12 fully matching, plus 53 partially matching documents found.

Latest Intelligence

Cortellis Drugs to Watch in 2020 report

as Kymriah and Yescarta.
25 Women Leaders in UK Healthcare (part 2)

It has brought to market not one but two groundbreaking drugs in hepatitis C, Harvoni, and in diffuse large B cell lymphoma, Yescarta, one of the first CAR-T therapies to
Bluebird: on a mission to ‘recode’ the DNA of healthcare

years. Kymriah’s US list price is $475, 000 while Gilead’s rival drug, Yescarta, is priced at $373, 000 (with European prices substantially lower than this).
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”

can make it on to the market early – agreements on the two CAR-T drugs, Novartis’ Kymriah and Gilead’s Yescarta providing an encouraging sign.
Cell and gene therapy

Cell and gene therapies are currently expensive to manufacture. We do not believe that recently marketed products, with US prices ranging from $373, 000 for Yescarta to $850, 000 for Luxturna,

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest from PMHub

Training the next generation of biotech leaders

In August, Novartis’ revolutionary CAR-T therapy, Kymriah, was approved. This was quickly followed by the approval of Kite’s Yescarta in October.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Healthcare Senior Account Manager: Competitive

Sales Director, Healthcare communications agency, London/ SE UK: Six figure salary

Account Director – Creative Healthcare Communications: Competative

Medical Editor: Competitive

Healthcare Lead Copywriter: Competitive

Account Manager Healthcare / Pharmaceutical Sector: Negotiable Salary

Healthcare Account Director: Competitive

PMHub

Add my company

Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

AstraZeneca’s focus on diagnosing and managing chronic kidney disease: People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...
Delphi Technique Virtual Co-creation: A Customer Story: How a client leveraged the Delphi technique to co-create a consensus statement and algorithm using virtual touchpoints....
Three ways AI will change healthcare in the next decade: Looking forward, there is no doubt that AI will continue to take centre stage in global healthcare initiatives...